ChiCTR2600119541 版本V1.0 版本创建时间2026/02/28 14:35:44 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600119541 

最近更新日期:

Date of Last Refreshed on:

2026-02-28 14:35:19 

注册时间:

Date of Registration:

2026-02-28 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

新型多功能口腔支架对接受放疗的头颈癌病人正常组织保护(剂量学分析)和辅助体位固定作用的临床研究

Public title:

Clinical Study on Normal Tissue Protection (Dosimetric Analysis) and Auxiliary Posture Fixation of a New Multifunctional Oral Stent in Head and Neck Cancer Patients Undergoing Radiotherapy

注册题目简写:

English Acronym:

研究课题的正式科学名称:

新型多功能口腔支架对接受放疗的头颈癌病人正常组织保护(剂量学分析)和辅助体位固定作用的临床研究

Scientific title:

Clinical Study on Normal Tissue Protection (Dosimetric Analysis) and Auxiliary Posture Fixation of a New Multifunctional Oral Stent in Head and Neck Cancer Patients Undergoing Radiotherapy

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李蒙妍 

研究负责人:

李蒙妍 

Applicant:

Li Mengyan 

Study leader:

Li Mengyan 

申请注册联系人电话:

Applicant telephone:

+86 136 6011 7146

研究负责人电话:

Study leader's
telephone:

+86 136 6011 7146

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

limengyan@sysush.com

研究负责人电子邮件:

Study leader's E-mail:

limengyan@sysush.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广东省深圳市光明区新湖街道圳园路628号

研究负责人通讯地址:

广东省深圳市光明区新湖街道圳园路628号

Applicant address:

No. 628, Zhenyuan Road, Xinhu Subdistrict, Guangming District, Shenzhen, Guangdong Province

Study leader's address:

No. 628, Zhenyuan Road, Xinhu Subdistrict, Guangming District, Shenzhen, Guangdong Province

申请注册联系人邮政编码:

Applicant postcode:

518000

研究负责人邮政编码:

Study leader's postcode:

518000

申请人所在单位:

中山大学附属第七医院(深圳)

Applicant's institution:

The Seventh Affiliated Hospital, Sun Yat-sen University (Shenzhen)

研究负责人所在单位:

中山大学附属第七医院(深圳)

Affiliation of the Leader:

The Seventh Affiliated Hospital, Sun Yat-sen University (Shenzhen)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-2026-025-01

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

中山大学附属第七医院(深圳)医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of The Seventh Affiliated Hospital, Sun Yat-sen University (Shenzhen)

伦理委员会批准日期:

Date of approved by ethic committee:

2026-01-23 00:00:00

伦理委员会联系人:

魏嘉亿

Contact Name of the ethic committee:

Wei Jiayi

伦理委员会联系地址:

广东省深圳市光明区新湖街道圳美社区海鑫光高新工业园F栋1楼

Contact Address of the ethic committee:

1st Floor, Building F, Haixinguang High-Tech Industrial Park, Zhenmei Community, Xinhu Subdistrict, Guangming District, Shenzhen, Guangdong Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 755 8120 7260

伦理委员会联系人邮箱:

Contact email of the ethic committee:

zsqyllwyh@sysush.com

研究实施负责(组长)单位:

中山大学附属第七医院(深圳)

Primary sponsor:

The Seventh Affiliated Hospital, Sun Yat-sen University (Shenzhen)

研究实施负责(组长)单位地址:

广东省深圳市光明区新湖街道圳园路628号

Primary sponsor's address:

No. 628, Zhenyuan Road, Xinhu Subdistrict, Guangming District, Shenzhen, Guangdong

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

广东省

市(区县):

深圳市

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

中山大学附属第七医院(深圳)

具体地址:

广东省深圳市光明区新湖街道圳园路628号

Institution
hospital:

The Seventh Affiliated Hospital, Sun Yat-sen University (Shenzhen)

Address:

No. 628, Zhenyuan Road, Xinhu Subdistrict, Guangming District, Shenzhen, Guangdong

经费或物资来源:

广州市卫健委基金,20241A011120

Source(s) of funding:

Guangzhou Municipal Health Commission Fund, No. 20241A011120

研究疾病:

头颈肿瘤  

Target disease:

Head and Neck Neoplasms

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机交叉对照 

Study design:

Cross-over 

研究目的:

评估新型多功能定制化压舌式口腔支架(硅橡胶材质)在头颈部肿瘤放疗中计量学优势以及在鼻咽癌患者中提升体位固定精度的有效性与可行性。  

Objectives of Study:

To evaluate the dosimetric advantages of a novel multifunctional customized tongue-depressing oral stent (silicone rubber material) in radiotherapy for head and neck tumors, as well as the effectiveness and feasibility of improving the accuracy of posture fixation in nasopharyngeal carcinoma patients.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.经病理确诊、拟接受根治性或辅助性放疗的头颈癌患者,包括鼻咽癌、鼻咽癌侵犯鼻腔和硬腭、鼻腔癌、鼻窦癌、软腭和硬腭癌、舌癌、牙龈癌及口底癌等; 2.年龄18~85岁之间,性别不限; 3.东部肿瘤协作组(Eastern Cooperative Oncology Group, ECOG)体能状态为0-2分; 4.没有口腔疾病,明显张口困难或严重颌面部畸形的患者; 5.病人签署知情同意书和与之相关的治疗同意书。

Inclusion criteria

1.Patients with histopathologically confirmed head and neck cancer scheduled to receive radical or adjuvant radiotherapy, including nasopharyngeal carcinoma, nasopharyngeal carcinoma with invasion of the nasal cavity and hard palate, nasal cavity cancer, paranasal sinus cancer, soft and hard palate cancer, tongue cancer, gingival cancer, floor of mouth cancer, etc; 2.Aged between 18 and 85 years, regardless of gender; 3.Eastern Cooperative Oncology Group (ECOG) performance status score of 0–2; 4.No oral diseases, obvious trismus, or severe maxillofacial deformities; 5.Patients have signed the informed consent form and relevant treatment consent forms.

排除标准:

1.不能理解和遵守研究方案的要求的患者; 2.有口腔疾病、明显张口困难或严重颌面部畸形的患者; 3.缺牙影响支架稳定和重复性的患者; 4.硅橡胶材料过敏患者。

Exclusion criteria:

1.Patients who are unable to understand and comply with the requirements of the study protocol; 2.Patients with oral diseases, obvious trismus, or severe maxillofacial deformities; 3.Patients with tooth loss affecting the stability and repeatability of the stent; 4.Patients with allergy to silicone rubber materials.

研究实施时间:

Study execute time:

From 2026-03-01 00:00:00 To 2026-08-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-03-01 00:00:00 To 2026-06-30 00:00:00

干预措施:

Interventions:

组别:

顺序1组

样本量:

4

Group:

Sequence Group 1

Sample size:

干预措施:

先接受 “佩戴口腔支架 + 调强放射治疗(IMRT)”(A 期,17 次放疗),后接受 “不佩戴口腔支架 + IMRT”(B 期,16 次放疗)

干预措施代码:

Intervention:

First receive "oral stent placement + intensity-modulated radiotherapy (IMRT)" (Phase A, 17 fractions),then receive "no oral stent placement + IMRT" (Phase B, 16 fractions).

Intervention code:

组别:

顺序2组

样本量:

4

Group:

Sequence Group 2

Sample size:

干预措施:

先接受 “不佩戴口腔支架 + IMRT”(B 期,17 次放疗),后接受 “佩戴口腔支架 + 调强放射治疗(IMRT)” (A 期,16 次放疗)。

干预措施代码:

Intervention:

First receive "no oral stent placement + IMRT" (Phase B, 17 fractions), followed by "oral stent placement + intensity-modulated radiotherapy (IMRT)" (Phase A, 16 fractions).

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

广东省 

市(区县):

深圳市 

Country:

China

Province:

Guangdong

City:

Shenzhen

单位(医院):

中山大学附属第七医院(深圳) 

单位级别:

三甲 

Institution
hospital:

The Seventh Affiliated Hospital, Sun Yat-sen University (Shenzhen)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

舌、腮腺正常组织的剂量学参数(Dmean、Dmin、Dmax)

指标类型:

主要指标

Outcome:

Dosimetric parameters of normal tissues (tongue, parotid gland): Dmean, Dmin, Dmax

Type:

Primary indicator

测量时间点:

放疗计划评估完成后

测量方法:

在放疗计划系统(TPS)中,由专业放射治疗物理师按照统一标准勾画舌、腮腺正常组织轮廓,在最终确认的放疗计划中,分别提取并记录舌、腮腺的剂量学参数,包括平均剂量(Dmean)、最小剂量(Dmin)、最大剂量(Dmax)。所有剂量参数均由同一物理师在相同计划系统与评估标准下完成测量,保证测量一致性与准确性。

Measure time point of outcome:

After the completion of radiotherapy plan evaluation.

Measure method:

The tongue and parotid glands were delineated as organs at risk in the treatment planning system (TPS) by a professional radiation therapy physicist according to a unified standard. The dosimetric parameters, including mean dose (Dmean), minimum dose (Dmin), and maximum dose (Dmax) of the tongue and parotid glands, were extracted and recorded from the finalized radiotherapy plan. All dose parameters were measured by the same physicist using the same planning system and evaluation criteria to ens

指标中文名:

鼻咽癌患者放疗期间每次 CBCT 测量的X、Y、Z 轴等三维方向的摆位误差(mm)

指标类型:

次要指标

Outcome:

Setup errors (mm) in the three-dimensional directions (X, Y, Z axes) measured by CBCT before each fraction during radiotherapy in patients with nasopharyngeal carcinoma.

Type:

Secondary indicator

测量时间点:

每次放疗前,完成摆位及CBCT扫描并完成配准后

测量方法:

患者每次放疗前行锥形束 CT(CBCT)扫描,将 CBCT 图像与计划 CT 图像进行自动配准及手动微调,由放射治疗技师按照统一标准记录 X、Y、Z 轴三维方向的摆位误差值,单位为毫米(mm)。

Measure time point of outcome:

Before each radiotherapy fraction, after patient setup, CBCT scan and image registration are completed.

Measure method:

Cone-beam computed tomography (CBCT) scan is performed before each radiotherapy fraction. The CBCT images are registered with the planning CT images by automatic registration and manual adjustment. The setup errors in the three-dimensional directions of X, Y, and Z axes are recorded by radiation therapists according to a unified standard, with the unit of millimeter (mm).

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

None

Tissue:

None

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

None

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由研究医生生成随机分配序列的软件:采用 SAS 9.4 统计软件,通过 PROC SURVEYSELECT 过程步生成随机分配序列,确保序列生成的科学性与随机性。 随机化类型:简单随机化(完全随机化)。 限制及详细信息:无额外分层或区组设计,仅按 1:1 比例将 8 例鼻咽癌患者随机分配至顺序 1 组(先 A 期后 B 期)和顺序 2 组(先 B 期后 A 期)。因总样本量仅 8 例(每组 4 例),简单随机化可满足组间基线平衡需求,且操作简便、易于执行,无需复杂的区组设定或分层因素调整,能高效完成分组并保障研究设计的可行性。

Randomization Procedure (please state who generates the random number sequence and by what method):

Software for generating random allocation sequence by research physicians: SAS 9.4 statistical software was used to generate the random allocation sequence via the PROC SURVEYSELECT procedure, ensuring the scientificity and randomness of sequence generation. Type of randomization: Simple randomization (complete randomization). Restrictions and detailed information: No additional stratification or block design was applied. A total of 8 nasopharyngeal carcinoma patients were randomly assigned to Sequence Group 1 (Phase A followed by Phase B) and Sequence Group 2 (Phase B followed by Phase A) at a 1:1 ratio. Given the total sample size of only 8 patients (4 patients per group), simple randomization can meet the requirement of baseline balance between groups, with the advantages of simple operation and easy implementation. There is no need for complex block setting or adjustment of stratification factors, which enables efficient group allocation and ensures the feasibility of the study design.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

按试验流程收集相关数据并将其填入病人的CRF表,每天均记录体位固定误差。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Collect relevant data in accordance with the trial process and fill it into the patient’s Case Record Form (CRF), and record the posture fixation error every day.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-02-28 14:35:19